1 / 9

Celebrating our success

Celebrating our success. Dr Jon Hunt, Deputy Director of RDSO. A successful year for the University so far. Over £32.5M awarded via 233 grants Biggest funder still EPSRC (£17M) EU commission £4.6M (compared to £3.8M for whole of last year)

cael
Download Presentation

Celebrating our success

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Celebrating our success Dr Jon Hunt, Deputy Director of RDSO

  2. A successful year for the University so far • Over £32.5M awarded via 233 grants • Biggest funder still EPSRC (£17M) • EU commission £4.6M (compared to £3.8M for whole of last year) • UK industry currently at £1.8M (exc. £2.7M from WW) (compared to £4M for whole of last year) • 12 awards above £500k, 4 above £1M(RD&C, e.g. Raithby, WW, ESRC...)

  3. Research volume University of Bath income 2012: £196M QR QR~£17M + ext fund ~£27M = Research £44M income pa

  4. Threats • Pressures leading to reduction in overall research funding: • Post-REF: • QR income reduction, maybe up to 25% (£4M) • External income need to maintain or grow • Increased focus on critical mass investments • CSR 2015 will question Research Council budgets • Charities have less funding due to recession • Alliances between universities, e.g. N8, M5 and SES5

  5. Strengths • Good reputation: funders • Excellent outputs recognised by HEFCE • Pockets of critical mass • Strongly collaborative culture • Strategic partner with EPSRC (our major funder)

  6. Weaknesses • Unbalanced portfolio • Capacity: Burn out • Pockets of experience with European funding • Very little funding from other Research Councils • Limited business investments • Pathways to impact not taken seriously

  7. Opportunities • Funders still open for business • Research Councils and TSB • Europe: ERC, Marie Curie, Collaborative R&D, InterReg (inter-regional network grants) • Charities • Industry • How do we widen the pool of grant holders? • How to strengthen relationships with industry?

  8. What’s my plan? • ADRs: priorities e.g. centres & institutes • Get into Europe • ERC • InterReg (inter-regional networking grants) • Marie Curie fellowships • Lobbying for priority areas (in H2020) • Treat pathways to impact plan as value chains to build relations to secure future business income • Network with other HEIs to access non-EPSRC funds • ECR program (currently H&SS) • Support for ‘calls for proposals’ and institutional bids

  9. Our help We’re here to help (Research Development): • Dr Caroline Ang • Dr Gareth Buchanan • Dr Susie Douglas • Dr Alison Evans • Dr Jon Hunt • Sarah Jones

More Related